Evidence map›Paper›PMID 32256811›Full record

ArticleOncology letters2020

Differential behavior of NF-κB, IκBα and EGFR during the renal carcinogenic process in an experimental model

Telma Pariente-Pérez, Francisco Aguilar-Alonso, José Dolores Solano, Chabetty Vargas-Olvera, Patricia Curiel-Muñiz, Carmen Adriana Mendoza-Rodríguez, Daniela Tenorio-Hernández, María Elena Ibarra-Rubio

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Telma Pariente-PérezBiology Department, Faculty of Chemistry, Laboratory F-225, National Autonomous University of Mexico, CDMX 04510, Mexico.
Francisco Aguilar-AlonsoBiology Department, Faculty of Chemistry, Laboratory F-225, National Autonomous University of Mexico, CDMX 04510, Mexico.
José Dolores SolanoBiology Department, Faculty of Chemistry, Laboratory F-225, National Autonomous University of Mexico, CDMX 04510, Mexico.
Chabetty Vargas-OlveraBiology Department, Faculty of Chemistry, Laboratory F-225, National Autonomous University of Mexico, CDMX 04510, Mexico.
Patricia Curiel-MuñizBiology Department, Faculty of Chemistry, Laboratory F-225, National Autonomous University of Mexico, CDMX 04510, Mexico.
Carmen Adriana Mendoza-RodríguezBiology Department, Faculty of Chemistry, Laboratory F-323, National Autonomous University of Mexico, CDMX 04510, Mexico.
Daniela Tenorio-HernándezBiology Department, Faculty of Chemistry, Laboratory F-225, National Autonomous University of Mexico, CDMX 04510, Mexico.
María Elena Ibarra-RubioBiology Department, Faculty of Chemistry, Laboratory F-225, National Autonomous University of Mexico, CDMX 04510, Mexico.
Universidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is the most common type of cancer of the adult kidney. It is generally asymptomatic even at advanced stages, so opportune diagnosis is rare, making it almost impossible to study this cancer at its early stages. RCC tumors induced by ferric nitrilotriacetate (FeNTA) in rats histologically correspond to the human clear cell RCC subtype (ccRCC) and the exposure to this carcinogen during either one or two months leads to different early stages of neoplastic development. High levels of nuclear factor kappa B (NF-κB) and epidermal growth factor receptor (EGFR) as well as low levels of NF-κB inhibitor alpha (IκBα) are frequent in human RCC, but their status in FeNTA-induced tumors and their evolution along renal carcinogenesis is unclear. On this basis, in the present study NF-κB, IκBα and EGFR behavior was analyzed at different stages of the experimental renal carcinogenesis model. Similar to patients with RCC, neoplastic tissue showed high levels of p65, one of the predominant subunits of NF-κB in ccRCC and of EGFR (protein and mRNA), as well as a decrease in the levels of NF-κB's main inhibitor, IκBα, resulting in a classic oncogenic combination. Conversely, different responses were observed at early stages of carcinogenesis. After one month of FeNTA-exposure, NF-κB activity and EGFR levels augmented; but unexpectedly, IκBα also did. While after two months, NF-κB activity diminished, but EGFR and IκBα levels remained elevated. In conclusion, FeNTA-induced tumors and RCC human neoplasms are analogues regarding to the classic NF-κB, IκBα and EGFR behavior, and distinctive non-conventional combination of changes is developed at each early stage studied. The results obtained suggest that the dysregulation of the analyzed molecules could be related to different signaling pathways and therefore, to particular effects depending on the phase of the carcinogenic process.

Indexed as

carcinogenesisclear cell renal cell carcinomaepidermal growth factor receptorexperimental model in vivoferric nitrilotriacetateIκBαNF-κBp65

Identifiers

PMID32256811
PMCPMC7074249
OpenAlexW3010331092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.